Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07278089

AF Screening in Patients With Abnormal Echocardiographic Parameters

To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Taipei Veterans General Hospital

Taipei, 112, Taiwan

Location status: Recruiting

Location contact

Taipei Veterans General Hospital

CONTACT

[email protected]

886-2-28712121

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients who met any of the following criteria

  • LAE: defined as LAD ≥ 45 mm or LAVI > 34 ml/m2;
  • LVH: defined as LV septal or posterior wall thickness ≥ 15 mm;
  • E/e' > 14;
  • grade II or III diastolic dysfunction;
  • VHD;
  • HF: defined as LVEF < 40% or LVEF ≥40% with clinical presentation compatible with Framingham criteria, New York Heart Association functional classification II-IV, and N-terminal pro-B type natriuretic peptide (NT-proBNP) > 125 pg/ml.

Exclusion criteria

  • Patients with a history of AF or atrial flutter, congenital heart disease, acute coronary syndrome undergoing urgent percutaneous coronary intervention within 3 months, uncontrolled hyperthyroidism, end-stage renal disease, unstable hemodynamic status or any known major comorbidities or medical conditions with expected life expectancy less than 1 year are excluded.

Treatment and study plan

Study Arm

Diagnostic Test

Scheduled cardiac rhythm monitoring every 3 months using extended continuous ECG monitoring

Primary outcomes

  1. the detection of AF either by 12-lead ECG or any episodes of AF lasting ≥ 30 seconds by the single-lead ECG or 7-day continuous recording.

    Time frame: 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Tze-Fan Chao, PhD

CONTACT

[email protected]

886-2-28727794

Sponsors and collaborators

Lead sponsor

Tze-Fan Chao

Other Gov

Registry information

Official study title

Screening of Atrial Fibrillation/Arrhythmia Events in Patients With Abnormal Echocardiographic Parameters: The Randomized, Prospective SAFE-ECHO Study Design and Rationale

Acronym: SAFE-ECHO

Important dates

Study start
2025
Primary completion
2031
Study completion
2032
First posted
Dec 11, 2025
Registry last updated
Dec 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.